Pretoria, 5 October 2022 - The South African Health Products Regulatory Authority (SAHPRA) has recently been ranked by the World Health Organisation (WHO) at a functional level of maturity (Level 3) according to WHO’s global classification system for national medical products regulatory authorities. This means...
UPDATE ON COVID-19 HEALTH PRODUCTS: SAHPRA registers the Covovax COVID-19 vaccine from Cipla (Pty) Ltd and additional indication of use of COVID-19 vaccine MC Pharma from MC Pharma (Pty) Ltd in the age group 3 -17 years. Pretoria, 28 September 2022 – SAHPRA registered a COVID-19...
Patient safety resonates with SAHPRA’s mission of ensuring that the public is protected by registering and regulating all health products so that they comply with SAHPRA’s pillars of safety, quality, efficacy and performance. This involves ensuring that stringent regulatory requirements are followed before any health product is made...
Pretoria, 12 September 2022 - On the 04th of August 2022, SAHPRA issued a media statement relating to the first fatal case of GBS following vaccination with COVID-19 Vaccine Janssen. Recently, SAHPRA has been informed of a second fatal case of Guillain-Barré syndrome (GBS) following...
KwaZulu-Natal, 12 September 2022 – SAHPRA is planning on visiting universities that offer studies relating to pharmacy and medicines. These visits will create an awareness about SAHPRA to students. Its mandate and its roles and responsibilities include educating the students about the Authority’s programmes. There will...
Pretoria, 26 August 2022 – Representatives of the GHPP-PharmTrain Project, part of Germany’s Federal Ministry of Health and located at the Federal Institute for Drugs and Medical Devices (BfArM), visited the South African Health Products Authority (SAHPRA) to discuss future collaboration in capacity-building. The project...
Pexels via Pixabay...
Johannesburg, 06 August 2022 - The South African Health Products Regulatory Authority (SAHPRA) was invited to speak at this year’s South African Association of Pharmacists in Industry (SAAPI) Conference during 03-05 August 2022 sharing vital information across core functional areas of the organisation. SAHPRA was...
04 August 2022 On 31 March 2021, SAHPRA approved the use of the COVID-19 Vaccine Janssen for individuals 18 years of age and older as a single primary vaccination dose. COVID-19 Vaccine Janssen was later approved as a single booster dose given at least two months...
18 July 2022 Finding the current form Download the current radionuclides application forms from the Health Products tab on the SAHPRA website: www.sahpra.org.za/radiation-control-application-and-report-forms – or click here. The document called Overview of Radionuclides (RN) application and report forms will give you the number/name of the form you...
